Quad induction for all, including in many aged > 80 with steroid-sparing approach! Deciding on myeloma induction now based on whether/not pt may receive ASCT later always felt like putting cart before 🐎… With new approvals, thankfully these #MMsm gymnastics no longer needed.

Key Highlights of Zongertinib (Hernexeos) #FDA Approval 1. First Oral Treatment Option: While previous therapies for HER2-mutant lung cancer required intravenous (IV) infusion, Zongertinib is the first FDA-approved oral (pill) treatment for this specific patient group. 2. High Target Selectivity: It is specifically designed as a "HER2-selective" TKI, meaning it targets mutated HER2 receptors without affecting other similar receptors like EGFR. 3. Improved Side Effect Profile: Thanks to its high selectivity, it avoids the severe diarrhea and skin rashes often caused by older generation drugs that also inhibited EGFR, offering a more tolerable treatment for patients. 4. Efficacy Against Brain Metastases: Zongertinib has demonstrated a significant ability to cross the blood-brain barrier, providing a breakthrough treatment option for managing brain metastases in lung cancer patients.

20 years in the making! #ASCOGU26 delivers a historic paradigm shift in Muscle-Invasive Bladder Cancer. KEYNOTE-B15 (LBA630) demonstrates that perioperative EV Pembrolizumab unequivocally outperforms the platinum chemo standard in cisplatin-eligible MIBC. A new global standard of care is officially established. #BladderCancer #MIBC #Oncology #UroOnc #MedTwitter #ASCO @ASCO

Our own @MattMossanen at #GU26 @ASCO , discussing how we can support women diagnosed with bladder cancer ➡️ stop repeated UTI treatment, refer ASAP to urology for an office cystoscopy takes , it takes less than 5 minutes!!! @DanaFarber_GU @MGBUrology

🫁 Amivantamab Lazertinib in Atypical EGFR NSCLC: CHRYSALIS-2. In 105 pts with advanced NSCLC harboring atypical EGFR mutations (G719X, L861Q, S768I), Amivantamab Lazertinib achieved: • ORR 52% • mPFS 11.1 mo • mDoR 14.1 mo • mOS NE Tx-naïve: ORR 57%, mPFS 19.5 mo. Single-arm study. Meaningful activity in a historically underserved subgroup. 📖 @JCO_ASCO doi.org/10.1200/JCO-24-02835 #CánCare #NSCLC #EGFR #TargetedTherapy #lcsm

I am reminded once again that research matters. My wife’s friend was diagnosed with metastatic ovarian cancer, resistant to our favorite drug Cis/Carboplatin. Genetic testing revealed, among other things, KRAS G12A mutation. She was started on a KRAS inhibitor but unfortunately developed massive myopathy to the point she could barely walk. At that point, she needed bilateral nephrostomy tubes for renal blockage and was given weeks to live. But her mutation panel had also revealed modestly elevated tumor mutation burden (TMB) and CHEK2 mutation, which is involved in DNA damage response. Based on this (though the evidence was limited), she was started on immune checkpoint blockade (ICB) as a last-ditch effort. Since then, her tumors have melted away, and our friend is now strong enough to clear the snow during LAST NIGHT's blizzard in Northeast. Below is a photo she just sent us. I share not just because this is a miracle, but a SCIENCE IN ACTION! #SpartansWill #ResearchSavesLives @MSUMD, @MSU_Medicine, @HFH_MSU_HS

Evidence is accumulating. Consistent with our meta-analysis presented at #ESMO25, this retrospective cohort shows that first-line CDK4/6 ET leads to shorter PFS in pathogenic BRCA1/2 and PALB2 carriers! thebreastonline.com/article/…

T-DXd has revolutionized the treatment of HER breast cancer, yet predictive biomarkers are critically needed An exploratory biomarker analysis of DestinyBreast trials is now out in @Annals_Oncology 👇🏻 @OncoAlert

The largest randomized trial of medical A.I. —Over 100,000 women in Sweden —radiologist AI vs 2 radiologists, in follow-up —AI added led to 29% more cancer detected, 44% reduced workload, and —Less cancer dx in subsequent 2 years, and, when found, less aggressive thelancet.com/journals/lance…

Precision oncology in stage IV NSCLC is no longer optional. It is the backbone of care. 🧬🫁 One diagnosis. Multiple molecular roads. Very different treatments. What matters first? Broad NGS upfront. Always. 🔹 EGFR alterations Exon 19 del / L858R: osimertinib ± chemo or amivantamab lazertinib Exon 20 insertions: chemo amivantamab Resistance pathways now include MET, T790M, ADCs, bispecifics 🔹 ALK, ROS1, RET, METex14, BRAF V600E, NTRK Highly effective targeted TKIs upfront Sequencing matters more than ever after progression 🔹 KRAS G12C, HER2 exon 20, NRG1 Targeted options mainly in later lines ADCs and next-gen TKIs changing outcomes Key takeaway 👇 Stage IV NSCLC is not one disease. Treat the driver, not just the histology. 📌 Broad molecular testing at diagnosis = survival-defining decision. #OncoTwitter #MedTwitter #LungCancer #NSCLC #PrecisionOncology #TargetedTherapy #CancerGuidelines @asco @JCO_ASCO @myESMO @OncoAlert

All my 2026 current myeloma algorithms in one thread. From smoldering to newly diagnosed to relapsed. Bookmark! #ASH25 #ASH25VR 1/ Smoldering Myeloma Main message: I recommend Daratumumab X 3 years for high risk smoldering myeloma.

⏱️ Oncologists: save patients time & reduce infusion center overload - infuse pembro in 10 minutes instead of 30. ⏱️ Safety data now out in @JCOOP_ASCO, IRR low (4%) & similar to 30 min infusion. @Oncoalert @JCO_ASCO ascopubs.org/doi/10.1200/OP-…

I LOVE “less may be more” trials. SUPREMO gives us cleaner language for the PMRT gray zone (post-mastectomy, intermediate-risk: pT1N1/pT2N1/pT3N0 or pT2N0 w grade 3/LVI; modern systemic therapy; margins ≥1 mm). What it found at ~10 years: • OS: 81.4% w chest-wall RT vs 81.9% w/o (HR 1.04) — no survival benefit • DFS/DMFS: no meaningful difference • Chest-wall recurrence: 1.1% vs 2.5% (HR 0.45) — <2% absolute benefit • LRR: 2.7% vs 4.5% (HR 0.61; CI crosses 1) — directionally better Takeaway: In this risk band, chest-wall RT looks like a *small local-control lever*, not a survival lever. So the real question is: what’s this patient’s baseline 10-year LRR, and is that absolute reduction worth the tradeoffs (reconstruction goals, lung/heart dose, lymphedema, patient priorities)? Patient perspective: RT mainly lowers a small chance of local recurrence; survival and distant recurrence weren’t improved. Let’s decide if that absolute reduction is worth it for me. Source: doi.org/10.1056/NEJMoa241222…

Locally advanced rectal cancer is no longer automatically a trimodality, surgery-first disease. This review pulls together the total neoadjuvant therapy (TNT), watch‑and‑wait, and dMMR‑IO data into one question: for which patients is a stoma now optional—and how safe is that bet in community practice? Source: doi.org/10.1146/annurev-med-…

And dont forget the Five S Rules in #ILD management, as published by my dear friend @PTarantinoMD, wonderful mnemonic for us to remember for our patients, and management guidleines @TumorBoardTues

🛑 Stop treating AML like it’s 1990. We used to just blast the marrow with chemo. Now we are doing molecular micro-surgery. The star of #ASH25 is the Menin Inhibitor (Revumenib or Ziftomenib). Here is why this feels like Sci-Fi: ❤️‍🩹 1. The Toxic Couple In KMT2A-rearranged leukemia, two proteins cling to each other: Menin KMT2A. As long as they hold hands, the leukemia program stays ON. The cell remains an immature, furious blast. 💊 2. The Breakup The drug does not kill the cell with poison. It slides between them like a wedge. Handshake broken. Switch flipped OFF. ✨ 3. The Magic Trick The blast realizes it was never meant to be a rebel. It grows up into a neutrophil. Does its job. Then quietly retires. ⚠️ Clinical Pearl This sudden awakening can trigger Differentiation Syndrome. Fever, hypoxia, weight gain. It looks like infection but signals the drug is doing exactly what it should. Treat with steroids along with supportive care. Precision Oncology has finally entered AML. #Leukemia #MedEd #Oncology @OncoAlert @ASCO @myESMO

Aza Ven >>> IC for select ND-AML 💪🏽 The goal is to get into CR and consolidate with allo. Allo works best if you are fit enough to survive it! Aza-ven gets you there in better shape 💪🏽 Congratulations to Dr. Fathi et al 🙌🏽 #ASH25

#ASHkudos to @SLentzsch This is the nicest and most succinct explanation I’ve seen for CAR-T before bsAbs in myeloma 👏 And I agree! Even once MajesTEC-3 approved based on #ASH25 results, please make sure #MMsm pts hear about BCMA CAR-T as an option before starting bsAbs!

Love improved #communication studies like this #pallonc #supponc

In cancer care, health literacy doesn’t just shape understanding—it shapes experience. A population study (PROFILES registry) found that even among high–health literacy patients, those with rare cancers reported lower satisfaction, information access, and quality of life than those with common cancers. In lower–HL groups, gaps narrowed—but outcomes still fell across the board. The takeaway: information equity isn’t just about simplifying language. It’s about tailoring communication to context, rarity, and need—especially for those facing cancers that don't get the same share of voice as others. Source: doi.org/10.1007/s13187-025-0… #leusm, #MedTwitter, #OncTwitter